Apigenin is an edible plant-derived flavonoid that shows modest anti-tumor activities in vitro 
Introduction
Colon cancer is one of the leading causes of cancer-related deaths in the United States and worldwide. Since conventional therapeutic approaches are limited in treatment of advanced colon cancer and in prevention of the disease recurrence. Small molecule inhibitors have been developed under preclinical and clinical studies to treat colon cancer. Apigenin (see chemical structure in Supplementary Fig. S1A ) is one of the most common flavonoids widely present in fruits and vegetables. As a plant-derived natural compound, it is a promising and safe anti-tumor agent (1) (2) (3) (4) (5) . Studies have shown that apigenin induces cell cycle arrest and causes apoptosis in different cancer cells including colon cancer through modulation of diverse survival and death effectors, such as PI3K, AKT, ERK, STAT3, JNK and Mcl-1 (6-10). However, apigenin only showed a modest antitumor activity towards cancer cells (2, 11) . New strategies are needed to enhance apigenin's antitumor efficacy.
The PI3K-AKT and Ras-ERK pathways are two of the most important signaling cascades that transduce signals from transmembrane receptors to the nucleus to regulate cell proliferation and survival (12, 13) . Gain-of-function mutations in genes of these two signaling pathways, such as Ras, PIK3CA, and Raf are frequently observed in malignant tumors (14) (15) (16) . Their aberrant activation correlates with poor efficacy of chemotherapies and acquired drug resistance (17) (18) (19) . Author Manuscript Published OnlineFirst on October 14, 2013; DOI: 10.1158/1535-7163. or Bad and downregulates the pro-survival proteins Bcl-2 and Mcl-1. These effects were significantly enhanced by co-treatment with the BH3 mimetic inhibitor ABT-263 or ABT-737 (20) (21) (22) (23) .
ABT-263 (Navitoclax, see chemical structure in Supplementary Fig. S1B ) is an orally active analogue of ABT-737. The BH3 mimetic inhibitors were designed to induce apoptosis by blocking functions of the pro-survival Bcl-2 family proteins such as Bcl-XL, Bcl-2, and Bcl-w but not Mcl-1 or A1 (24) . Currently, combination of ABT-263 with other FDA-approved drugs against leukemia or solid tumors is being tested in clinical trials. However, tumor cells expressing high levels of Mcl-1 show resistance to ABT-263 or ABT-737 (25) . After long exposure, resistance to ABT-737 is acquired, at least partially resulting from the upregulation of Mcl-1 and/or A1 (26) . Therefore, limiting Mcl-1 expression with other agents offers a strategy to conquer acquired resistance and to enhance the anti-tumor efficacy of ABT-263 or ABT-737 (27, 28 ).
In the current study, we investigated the role of apigenin, a plant-derived natural compound, in sensitization of colon cancer cells to ABT-263 in vitro and in vivo. Our results indicate that in addition to Mcl-1, apigenin is also linked to inactivation of the AKT and ERK pathways to enhance the anti-tumor effect of ABT-263.
Materials and Methods

Reagents
Fetal bovine serum (FBS) was obtained from Atlanta Biological (Atlanta, GA). Culture medium and other related cell culture reagents were from Invitrogen (Carlsbad, CA). Apigenin, ABT-263, MK2206, and AZD6244 were purchased from ChemieTek (Indianapolis, IN). 
Western blotting
Whole cell lysates were prepared with cell lysis buffer (Cell Signaling Technologies, MA, USA), separated on SDS-PAGE electrophoresis and transferred to PVDF membrane (Bio-Rad, Hercules, CA). Blots were probed with polyclonal or monoclonal antibodies against Mcl-1, AKT1, AKT, phospho-AKT (S473), phospho-ERK1/2 (T202/Y204), ERK1/2, Bim, XIAP (Cell Signaling Technologies, MA, USA), Bax, Bcl-2, Bcl-XL, Bcl-w or β-actin (Santa Cruz Biotechnology, Santa Cruz, CA). Total RNA was extracted from the samples with Trizol reagent (Invitrogen, Carlsbad, CA, USA), and first-strand cDNA was generated using SuperScript III First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA) according to the manufacturer's instructions. Fluorogenic Taqman probes were obtained from Applied Biosystems. Mcl-1 mRNA was quantified by realtime PCR (ABI PRISM 7700 Sequence Detection System, Applied Biosystems). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as an internal control for normalization.
Real time PCR
Detection of Bax conformational change
Cells were lysed in a lysis buffer containing 2% CHAPS, 150 mM NaCl, 50 mM Tris HCl, pH Phosal 50 PG and administered by oral gavage. The control group received the vehicle only, and the treatment groups received apigenin, ABT-263, or both. ABT-263 was used at 100 mg/kg daily and apigenin at 25 mg/kg daily. For combination treatment, the agents were formulated at a higher concentration so that the total volume of the two agents together was equivalent to the volume of each agent alone. At the end point, mice were sacrificed and tumors were harvested for western blotting analysis.
Statistical analysis
Data from studies were expressed as the mean ± standard deviation. The statistical significances of differences between groups were determined using student's t-test. Difference was considered statistically significant if p < 0.05. Fig. S2D ), confirming that co-treatment with ABT-263 and apigenin caused apoptotic cell death via a caspase-dependent mechanism.
Downregulation of Mcl-1 by apigenin sensitized colon cancer cells to ABT-263-triggered cell death
As previously reported, expression or induction of Mcl-1 is a major obstacle to pro-apoptotic effect of ABT-263 (26, 27) . Mcl-1 was detectable in multiple colon cancer cell lines including HCT116, DLD1, SW48, HT29 and HCT-8 ( Supplementary Fig. S3 ). In HCT116 and DLD1 cells, apigenin downregulated Mcl-1 expression in a dose-and time-dependent manner ( Fig. 2A) . In 
to apigenin induced decreases in Mcl-1 mRNA levels in HCT116 cells (Supplementary Fig.   S6B ), suggesting that apigenin downregulated Mcl-1 expression at mRNA level.
Inhibition of AKT by apigenin is another modulator of synergistic interaction with ABT-
263
As reported previously, the PI3K-AKT pathway was inhibited by apigenin in leukemia cells (9) . To figure out whether the AKT pathway was affected by apigenin and played a role in ABT-263 and apigenin-induced cell death in colon cancer cells, HCT116 and DLD1 cells were treated with increasing doses of apigenin for 24 hours. As shown in Fig. 3A , activation of AKT was dose-dependently inhibited by apigenin. HCT116 and DLD1 cells were then exposed to ABT-263 and apigenin alone or in combination for 24 hours. While ABT-263 had no effect on AKT activation, apigenin inhibited AKT in the absence and presence of ABT-263 (Fig. 3B) . To (Fig. 3D) . Enhanced cleavage of caspase 3 was also observed in the presence of MK2206 (Fig. 3E) . Together, these results suggest that inactivation of AKT contributes to ABT-263 and apigenin-induced anti-tumor responses in colon cancer cells. 
Apigenin inhibition of ERK contributes to synergistic interaction with ABT-263
In an effort to explore other potential mechanisms contributing to the synergistic role of apigenin in ABT-263-induced cell killing, we examined whether apigenin targets ERK, a prototype pro-survival regulator. As shown in Fig. 4A, apigenin further enhanced ABT-263 synergy compared to ERK2 knockdown cells (Fig. 4C) . Similarly, AZD6244, a MEK inhibitor (32), blocked ERK1/2 activation and augmented the pro-apoptotic activity of ABT-263 (Fig. 4D, E) . These results support a role of ERK suppression in ABT-263 and apigenin-induced cell death.
Co-treatment with apigenin and ABT-263 upregulated Bim and activated Bax
The Bcl-2 family members are important mediators of cell death and survival. It has been shown that the AKT and ERK pathways are linked to regulation of certain Bcl-2 family members including Bim (33, 34) . Upon treatment with apigenin, Bim-L expression was robustly upregulated in HCT116 cells (Fig. 5A, left; Supplementary Fig. S7A, left) . Co-treatment with ABT-263 and apigenin further enhanced Bim-L expression ( Fig. 5A, right; Supplementary Fig.   S7A, right) . When the cells were treated with a small molecule inhibitor of AKT or MEK, although expression of both Bim-EL and Bim-L was upregulated significantly ( Supplementary Fig. 7B ), Bim-L expression was increased more than Bim-EL (2.5 versus 1.7 fold, respectively, upregulation upon treatment with MK2206; 3.2 versus 2.2 fold upregulation upon treatment with AZD6244). Thus Bim-L is a common effector between apigenin and AKT or MEK inhibition. Since these cells express high levels of endogenous Bim-EL, the moderate increase in Bim-EL by AKT or MEK inhibitor may not be as important as Bim-L induction. This is also consistent with a previous observation that Bim-L is more potent than EL in inducing apoptosis (35) .
To determine whether there are any other potential mitochondrial Bcl-2 family members were involved in apigenin enhancement of ABT-263-induced cell death in colon cancer cells, HCT116 and DLD1 cells were treated with increasing doses of apigenin for 24 hours. Western blotting analysis did not detect any significant changes in the Bcl-2 family members including Bcl-2, Bcl-XL, Bcl-w and Bax (Supplementary Fig. S8 ).
However, Bim has been shown to directly activate Bax, leading to translocation of Bax from cytosol to the mitochondria where it triggers mitochondrial outer membrane permeabilization (MOMP) to induce apoptosis. Associated with this, Bax undergoes transformational change with exposure of its N-terminus, which could be recognized by the 6A7 antibody (36) . As shown in 
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The anti-tumor efficacies of ABT-263 and apigenin were further analyzed in SCID mice. The SCID mice bearing HCT116 xenografts were treated daily with ABT-263, apigenin or both of them for 21 days. The growth of the xenografts and body weights were monitored 3 times per week. As shown in Fig. 6A , either apigenin or ABT-263 alone resulted in approximately 30% inhibition of tumor growth as compared to the vehicle control group. Co-treatment with ABT-263 and apigenin caused more than 70% inhibition, significantly higher than single drug treatment groups. The mice from all groups maintained comparable body weights during the course of the drug treatment, indicating minimal detrimental effects of single or combinatory treatment (Fig. 6B) . When the tumor tissues were examined by immunoblotting, decreases in
Mcl-1 and in phosphorylation of AKT and ERK were observed in the groups treated with apigenin or apigenin and ABT-263 (Fig. 6C) , indicating that apigenin also targets these prosurvival modulators in vivo.
Discussion
In this study, we showed the synergistic interaction in colon cancer cells between ABT-263, a Fig S6) . It is worth noting that, similar to other studies (7) (8) (9) , the concentrations of apigenin we used in our study were high micromolar concentrations. This less ideal efficacy may be related to its limited permeability across cell membranes and its stability in culture and in vivo. Before the molecular targets of apigenin are fully resolved, apigenin may be synthetically developed into more stable and more membrane permeable compounds to enhance its anti-tumor efficacy. In 
